EMMESSA.BO · BSE
EMMESSAR BIOTECH & NUTRITION L
₹24.06
+0.25% (+₹0.06)
Prev. close
₹24
Volume
724
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About EMMESSAR BIOTECH & NUTRITION L
Emmessar Biotech & Nutrition Limited, a healthcare company, provides healthcare and nutritional products in India and internationally. The company operates through Healthcare and Rent on Lease Land segments. It also offers CalmCream, a multi-functional skin cream; Calm Cream RESQ, a skin cream used for burns from sun, radiation, heat and chemicals; Cute-N-Comely, a cosmetic skin cream; MagiCream, a cream used for post-surgical scars; and Muscle Flex Gel, a gel used to relieve pain from aching muscles. In addition, the company offers vedaceuticals, an ayurveda disease curing medicine. Further, it provides healthcare products for dermatology, Muscular Pains & Functions, osteoporosis, General Health, anti-ageing, cosmatics, and burns, including radiation. The company was formerly known as Emmessar Chemical Industries Ltd. and changed its name to Emmessar Biotech & Nutrition Limited in April 2000. Emmessar Biotech & Nutrition Limited was incorporated in 1992 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Mathurakavi Srinivasa Raghavan Ayyangar
Headquarters
Mumbai
Employees
18
Website
ebnl.orgExchange
View on BSE ↗Key stats
Market cap
₹12.02 Cr
P/E ratio (TTM)
30.5
EPS (TTM)
₹0.79
Beta (1Y · daily vs NIFTY 50)
0.17
Beta (5Y · monthly vs NIFTY 50)
0.91
Shares float
16.72 L
EPS · quarter ended Jun 2026
₹0.26
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹6.99 Cr | ₹36.50 L | ₹1.02 Cr | ₹55.51 L | ₹61.09 L | ₹37.08 L | |
| EBITDA | — | — | ₹-66.97 L | ₹91.02 L | ₹1.06 Cr | ₹68.20 L |
| ₹1.45 Cr | ₹47.50 L | ₹50.38 L | ₹74.96 L | ₹31.61 L | ₹43.57 L | |
| Diluted EPS | — | — | ₹0.99 | ₹1.48 | ₹0.63 | ₹0.87 |
Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹7.94 Cr | ₹8.74 Cr | ₹9.42 Cr | ₹9.78 Cr | |
| — | — | ₹8.21 L | ₹10.94 L | ₹0 | ₹0 | |
| Stockholders' equity | — | — | ₹6.66 Cr | ₹7.40 Cr | ₹7.71 Cr | ₹8.11 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹37.62 L | ₹64.46 L | ₹22.39 L | ₹26.52 L | |
| Investing cash flow | — | — | ₹-54.63 L | ₹-64.35 L | ₹-22.98 L | ₹-25.64 L |
| Financing cash flow | — | — | — | ₹0 | ₹35,000 | ₹1.42 L |
| Capital expenditure | — | ₹-30.56 L | ₹-2.63 L | — | — | ₹-85,000 |
| End cash position | — | — | ₹1.18 L | ₹1.29 L | ₹1.05 L | ₹3.35 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| EMMESSAR BIOTECH & NUTRITION L | ₹12.29 Cr | ₹24.6 | 31.1 | 1.51 | 5.4% | 0.00 | -39.3% | -36.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.